tbuckley/cabot-search huggingface dataset:
Combined Cardiac Fluorodeoxyglucose–Positron Emission Tomography/Magnetic Resonance Imaging Assessment of Myocardial Injury in Patients Who Recently Recovered From COVID-19
Authors: Kate Hanneman, Christian Houbois, Alice Schoffel, Dakota Gustafson, Robert M. Iwanochko, Bernd J. Wintersperger, Rosanna Chan, Jason E. Fish, Kathryn L. Howe, Paaladinesh Thavendiranathan
Journal: JAMA Cardiology (2022)

<h3>Importance</h3> Although myocardial injury can occur with acute COVID-19, there is limited understanding of changes with myocardial metabolism in recovered patients. <h3>Objective</h3> To examine myocardial metabolic changes early after recovery from COVID-19 using fluorodeoxyglucose–positron emission tomography (PET) and associate these changes to abnormalities in cardiac magnetic resonance imaging (MRI)–based function and tissue characterization measures and inflammatory blood markers. <h3>Design, Setting, and Participants</h3> This prospective cohort study took place at a single-center tertiary referral hospital system. A volunteer sample of adult patients within 3 months of a diagnosis of COVID-19 who responded to a mail invitation were recruited for cardiac PET/MRI and blood biomarker evaluation between November 2020 and June 2021. <h3>Exposures</h3> Myocardial inflammation as determined by focal fluorodeoxyglucose (FDG) uptake on PET. <h3>Main Outcomes and Measures</h3> Demographic characteristics, cardiac and inflammatory blood markers, and fasting combined cardiac<sup>18</sup>F-FDG PET/MRI imaging were obtained. All patients with focal FDG uptake at baseline returned for repeated PET/MRI and blood marker assessment 2 months later. <h3>Results</h3> Of 47 included patients, 24 (51%) were female, and the mean (SD) age was 43 (13) years. The mean (SD) interval between COVID-19 diagnosis and PET/MRI was 67 (16) days. Most patients recovered at home during the acute infection (40 [85%]). Eight patients (17%) had focal FDG uptake on PET consistent with myocardial inflammation. Compared with those without FDG uptake, patients with focal FDG uptake had higher regional T2, T1, and extracellular volume (colocalizing with focal FDG uptake), higher prevalence of late gadolinium enhancement (6 of 8 [75%] vs 9 of 39 [23%],<i>P</i> = .009), lower left ventricular ejection fraction (mean [SD], 55% [4%] vs 62% [5%],<i>P</i> &lt; .001), worse global longitudinal and circumferential strain (mean [SD], −16% [2%] vs −17% [2%],<i>P</i> = .02 and −18% [2%] vs −20% [2%],<i>P</i> = .047, respectively), and higher systemic inflammatory blood markers including interleukin 6, interleukin 8, and high-sensitivity C-reactive protein. Among patients with focal FDG uptake, PET/MRI, and inflammatory blood markers resolved or improved at follow-up performed a mean (SD) of 52 (17) days after baseline PET/MRI. <h3>Conclusions and Relevance</h3> In this study of patients recently recovered from COVID-19, myocardial inflammation was identified on PET in a small proportion of patients, was associated with cardiac MRI abnormalities and elevated inflammatory blood markers at baseline, and improved at follow-up.
Optimizing pancreatic cancer management with next generation imaging and liquid biopsy (CHANGE-PDAC).
Authors: Erica S Tsang, Eric Andrew Collisson, Zhen J. Wang, Sorbarikor Piawah, Taylor Sanchez, Margaret A. Tempero, Andrew H. Ko
Journal: Journal of Clinical Oncology (2022)

TPS640 Background: Pancreatic ductal adenocarcinoma (PDAC) is anticipated to become the second-leading cause of cancer-related deaths by 2030. Systemic therapy remains the mainstay of treatment for those with unresectable/metastatic disease. There is an urgent need for biomarkers to rapidly assess treatment response to spare patients from the significant toxicities and costs of an ineffective regimen, and to guide decision-making for a therapeutic switch with a higher chance of efficacy. Circulating tumor (ct)DNA and PET/MRI represent promising emerging biomarkers for early response prediction. This is a prospective non-randomized study examining the role of ctDNA and PET/MRI in adjudicating early treatment response among patients with unresectable locally advanced or metastatic PDAC receiving systemic therapy. Methods: Approximately 158 patients with advanced PDAC will be recruited at the time of initiation of a new line of treatment in either the first or later-line setting. Patients receiving both standard of care and/or experimental therapies are permitted to enroll. Research blood samples will be collected at pre-treatment, 48 hours, two weeks, one month, and two months after treatment start for analysis of mutant ctDNA (using the FoundationOne/Natera platform). PET/MRI will be performed at pre-treatment and 4 weeks post treatment. All patients must have an ECOG performance status of 0-2 and have radiographically measurable disease. Clinical data will be collected prospectively, including demographics, ECOG performance status, CA 19-9 levels, chemotherapy type and dose intensity, and clinical and radiographic assessment of treatment response using RECIST 1.1 criteria. Enrollment began in August 2021. The primary endpoint is the correlation between change in tumor-derived ctDNA with radiographic progression, as measured by the change in tumor size. The Wilcoxon rank sum test will be used to compare the change in ctDNA with treatment between response vs. resistance. Cox proportional hazard regression modelling will be used to correlate the change in ctDNA with progression-free survival and overall survival. Secondary endpoints include defining thresholds for early chemotherapy switch using dynamic and quantitative changes in ctDNA and PET/MRI biomarkers for use in future prospective trials, establishing the relationship between early changes in PET/MRI and treatment response/resistance, and developing a multivariable model combining ctDNA and PET/MRI biomarkers to predict treatment response/resistance.
CANADA
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Biological markers associated with response to gefitinib (ZD1839) in patients with breast cancer
Authors: E. Gutteridge, J. M. Gee, R. I. Nicholson, J. F. R. Robertson
Journal: Journal of Clinical Oncology (2004)

648 Background: In patients (pts) with breast cancer, increased epidermal growth factor receptor (EGFR)/HER2 signalling is associated with de novo hormone resistance and oestrogen receptor (ER)-negative phenotypes. EGFR signalling is a key growth regulator in ER-positive acquired tamoxifen-resistant (TAM-R) models where EGFR-TKIs (EGFR tyrosine kinase inhibitors) are potent inhibitory agents. Preliminary clinical data show that the EGFR-TKI gefitinib (‘Iressa’, ZD1839) may be an effective treatment for TAM-R breast cancer (Proc Am Soc Clin Oncol 2003; 22: 7, abs 23). Here we report on expression of ER, EGFR, HER2 and insulin-like growth factor receptor (IGF-1R) in pts enrolled in a Phase II study of gefitinib. Methods: Two groups of pts were recruited: an ER-positive TAM-R group (n=20) and an ER-negative group (n=27). Pts received oral gefitinib 500 mg/day. Immunostaining was performed for ER and EGFR expression and HER2/IGF-1R expression/phosphorylation, and was semiquantified by HScore. With the exception of ER, median HScore was used as the positivity cut-off point. SPSS statistical analysis was used to determine if marker expression predicted gefitinib response by UICC criteria at 6 months or time to progression (TTP). Results: Pretreatment samples were available for 35 pts: 13 ER-positive and 22 ER-negative. Although responders were seen in both groups, responses were more frequently observed in ER-positive (82%) than ER-negative pts (13%). All responders expressed EGFR (median HScore 30, range 10–65) but a higher incidence of progressive disease (p=0.015) and a shorter TTP (p=0.012) were recorded in pts with high EGFR expression (clinical benefit median 36.5, range 10–160; progressive disease median 80, range 5–230). HER2 expression was similar in ER-positive TAM-R pts (54.5%) and ER-negative pts (47.6%). In ER-positive pts, high levels of HER2 did not preclude a response to gefitinib. Expression of IGF-1R did not predict response. Conclusion: Further biomarker studies, ongoing in these patients, are required to characterise predictors of response. 'Iressa' is a trademark of the AstraZeneca group of companies Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca AstraZeneca AstraZeneca
Vitamin D Deficiency Predicts for Poor Overall Survival in Caucasian but Not African American Patients with Multiple Myeloma
Authors: Sarvari Venkata Yellapragada, Anna Frolov, Nathanael Fillmore, Pallavi Dev, Sumaira Shafi, Ifeorah Chizoba, Do Nhan, Do T Nhan, Nikhil Munshi
Journal: Blood (2018)
Table of Contents
Authors: Oladipo Akinkugbe, Rasheed Balogun, Fatiu Arogundade, Joyce Popoola, Ebun Bamgboye, Solomon Kadiri, Jacob Plange-Rhule, John Eastwood, Jürgen Floege, Tilman Drüeke, Barnaby Hole, Katharine Evans, Rhodri Pyart, M Davids, Carlota Gonzalez Bedat, Norio Hanafusa, David Harris, Kitty Jager, Vivekanand Jha, Kirsten Johansen, Stephen Mcdonald, Ikuto Masakane, Guillermo Rosa-Diez, Rajiv Saran, James Wetmore, Fergus Caskey, Juewan Kim, Jacqueline Scaffidi, P Coates, Yu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku, Sayna Norouzi, Samira Farouk, Matthew Sparks, Kay Chee, Jonathan Cheung, Ian De Boer, M Luiza Caramori, Juliana Chan, Hiddo Heerspink, Clint Hurst, Kamlesh Khunti, Adrian Liew, Erin Michos, Sankar Navaneethan, Wasiu Olowu, Tami Sadusky, Nikhil Tandon, Katherine Tuttle, Christoph Wanner, Katy Wilkens, Sophia Zoungas, Lyubov Lytvyn, Jonathan Craig, David Tunnicliffe, Martin Howell, Marcello Tonelli, Michael Cheung, Amy Earley, Peter Rossing, Adeera Levin, Rajiv Agarwal, William Herrington, Hiddo Heerspink, Johannes Mann, Shahnaz Shahinfar, Jo-Ann Donner, Dick De Zeeuw, Meg Jardine, Kenneth Mahaffey, Aliza Thompson, Mary Beaucage, Kate Chong, Glenda Roberts, Duane Sunwold, Hans Vorster, Madeleine Warren, Sandrine Damster, Charu Malik, Vlado Perkovic, Greg Knoll, Marie-Chantal Fortin, Jagbir Gill, Jeremy Grimshaw, David Hartell, Priscilla Karnabi, Christina Parsons, S Kim, Biruh Workeneh, Kenar Jhaveri, Helbert Rondon-Berrios, Marine Berquez, Jonathan Gadsby, Beatrice Festa, Richard Butler, Stephen Jackson, Valeria Berno, Alessandro Luciani, Olivier Devuyst, Jennifer Gallop
Journal: Kidney International (2020)
Medicine for Nurses and Other Public Health Workers.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Table of Contents
Authors: Wei Chen, Nina Caplin, Osama El, Shuchita Sharma, Maryanne Sourial, Michael Ross, Mina Sourial, Kalyan Prudhvi, Ladan Golestaneh, Vesh Srivatana, Rochelle Dalsan, Daniil Shimonov, Luis Sanchez-Russo, Sara Atallah, Jaime Uribarri, Sethu Madhavan, Kirsten Johansen, Pranav Garimella, Caitlin Hicks, Philip Kalra, Dearbhla Kelly, Sven Martens, Kunihiro Matsushita, Pantelis Sarafidis, Manish Sood, Charles Herzog, Michael Cheung, Michel Jadoul, Wolfgang Winkelmayer, Holger Reinecke, Anne Hu, Cameron Stewart, Jonathan Craig, Kate Wyburn, Henry Pleass, John Kanellis, Wai Lim, Jean Yang, Germaine Wong, Anna Peired, Elena Lazzeri, Francesco Guzzi, Hans-Joachim Anders, Paola Romagnani, Kyung Lee, G Luca, John Cijiang He, Mark Hanudel, Shirley Wong, Grace Jung, Bo Qiao, Victoria Gabayan, Anna Zuk, Tomas Ganz, Imane Bensaada, Blaise Robin, Joëlle Perez, Yann Salemkour, Anna Chipont, Marine Camus, Mathilde Lemoine, Lea Guyonnet, Hélène Lazareth, Emmanuel Letavernier, Carole Hénique, Pierre-Louis Tharaux, Olivia Lenoir, Liang Wu, Changjie Liu, Dong-Yuan Chang, Rui Zhan, Jing Sun, Shi-He Cui, Sean Eddy, Viji Nair, Emily Tanner, Frank Brosius, Helen Looker, Robert Nelson, Matthias Kretzler, Jian-Cheng Wang, Ming Xu, Wenjun Ju, Ming-Hui Zhao, Min Chen, Lemin Zheng, Michaela Fuchs, Katharina Broeker, Julia Schrankl, Nicolai Burzlaff, Carsten Willam, Charlotte Wagner, Armin Kurtz, Clément Mennetrey, Xavier Benoît D'journo, Stéphane Burtey, David Taïeb, Muneharu Yamada, Hitoshi Iwamoto, Osamu Konno, Yu Kihara, Isao Akashi, Masaaki Okihara, Takashi Oda, Shun Manabe, Masayo Sato, Hiroshi Kataoka, Toshio Mochizuki, Kosaku Nitta, Marion Rabant, Kathleen Dessaix, David Buob, Ombeline Fagniez, Ramayana Oana, Catherine Ailioaie, Christophe Johanet, Mohamad Legendre, Farah Mansour, Pierrette Habib, Boutros Haddad, Najat Joubran
Journal: Kidney International (2021)
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
Authors: Alessio Cortellini, Raffaele Giusti, Marco Filetti, Fabrizio Citarella, Vincenzo Adamo, Daniele Santini, Sebastiano Buti, Olga Nigro, Luca Cantini, Massimo Di Maio, Joachim G. J. V. Aerts, Emilio Bria, Federica Bertolini, Miriam Grazia Ferrara, Michele Ghidini, Francesco Grossi, Annalisa Guida, Rossana Berardi, Alessandro Morabito, Carlo Genova, Francesca Mazzoni, Lorenzo Antonuzzo, Alain Gelibter, Paolo Marchetti, Rita Chiari, Marianna Macerelli, Francesca Rastelli, Luigi Della Gravara, Stefania Gori, Alessandro Tuzi, Michele De Tursi, Pietro Di Marino, Giovanni Mansueto, Federica Pecci, Federica Zoratto, Serena Ricciardi, Maria Rita Migliorino, Francesco Passiglia, Giulio Metro, Gian Paolo Spinelli, Giuseppe L. Banna, Alex Friedlaender, Alfredo Addeo, Corrado Ficorella, Giampiero Porzio, Marcello Tiseo, Marco Russano, Alessandro Russo, David James Pinato
Journal: Journal of Hematology & Oncology (2022)

Abstract Family history of cancer (FHC) is a hallmark of cancer risk and an independent predictor of outcome, albeit with uncertain biologic foundations. We previously showed that FHC-high patients experienced prolonged overall (OS) and progression-free survival (PFS) following PD-1/PD-L1 checkpoint inhibitors. To validate our findings in patients with NSCLC, we evaluated two multicenter cohorts of patients with metastatic NSCLC receiving either first-line pembrolizumab or chemotherapy. From each cohort, 607 patients were randomly case–control matched accounting for FHC, age, performance status, and disease burden. Compared to FHC-low/negative, FHC-high patients experienced longer OS (HR 0.67 [95% CI 0.46–0.95], p = 0.0281), PFS (HR 0.65 [95% CI 0.48–0.89]; p = 0.0074) and higher disease control rates (DCR, 86.4% vs 67.5%, p = 0.0096), within the pembrolizumab cohort. No significant associations were found between FHC and OS/PFS/DCR within the chemotherapy cohort. We explored the association between FHC and somatic DNA damage response (DDR) gene alterations as underlying mechanism to our findings in a parallel cohort of 118 NSCLC, 16.9% of whom were FHC-high. The prevalence of ≥ 1 somatic DDR gene mutation was 20% and 24.5% ( p = 0.6684) in FHC-high vs. FHC-low/negative, with no differences in tumor mutational burden (6.0 vs. 7.6 Mut/Mb, p = 0.6018) and tumor cell PD-L1 expression. FHC-high status identifies NSCLC patients with improved outcomes from pembrolizumab but not chemotherapy, independent of somatic DDR gene status. Prospective studies evaluating FHC alongside germline genetic testing are warranted.
Commentaire de “Traitement de l'œsophage de Barrett par radiofréquence” (4 articles), pp. 359
Journal: Endoscopy (2008)

See also:Stepwise circumferential and focal ablation of Barrett’s esophagus with high-grade dysplasia: results of the first prospective series of 11 patientsEndoscopy 2008; 40(05): 359-369DOI: 10.1055/s-2007-995567See also:A prospective pilot trial of ablation of Barrett’s esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system) Endoscopy 2008; 40(05): 380-387DOI: 10.1055/s-2007-995587See also:Effective treatment of early Barrett’s neoplasia with stepwise circumferential and focal ablation using the HALO systemEndoscopy 2008; 40(05): 370-379DOI: 10.1055/s-2007-995589See also:Pilot series of radiofrequency ablation of Barrett’s esophagus with or without neoplasiaEndoscopy 2008; 40(05): 388-392DOI: 10.1055/s-2007-995747
Case 29-2018: A 31-Year-Old Woman with Infertility
Authors: Mounzer Agha, A Sara, H Steven
Journal: New England Journal of Medicine (2019)

vitro studies, 1 and suggests that it is an early driving pathogenic mechanism that might precede additional abnormalities that could be associated with more refractory disease.Hence, early up-front therapy with venetoclax may be more effective than treatment for relapsed or refractory disease.
Incidence and risk factors for postoperative pancreatic fistula in 2089 patients treated by radical gastrectomy: A prospective multicenter cohort study in China
Authors: Jianzhang Wu, Zhaoqing Tang, Gang Zhao, Lu Zang, Ziyu Li, Weidong Zang, Zhengrong Li, Jianjun Qu, Su Yan, Chaohui Zheng, Gang Ji, Linghua Zhu, Yongliang Zhao, Jian Zhang, Hua Huang, Yingxue Hao, Lin Fan, Hongtao Xu, Yong Li, Li Yang, Wu Song, Jiaming Zhu, Wenbin Zhang, Minzhe Li, Xinyu Qin, Fenglin Liu
Journal: International Journal of Surgery (2022)
SARS‐CoV‐2 triggered oxidative stress and abnormal energy metabolism in gut microbiota
Authors: Tuoyu Zhou, Jingyuan Wu, Yufei Zeng, Junfeng Li, Jun Yan, Wenbo Meng, Huawen Han, Fengya Feng, Jufang He, Shuai Zhao, Ping Zhou, Ying Wu, Yanlin Yang, Rong Han, Weilin Jin, Xun Li, Yunfeng Yang, Xiangkai Li
Journal: MedComm (2022)

Abstract Specific roles of gut microbes in COVID‐19 progression are critical. However, the circumstantial mechanism remains elusive. In this study, shotgun metagenomic or metatranscriptomic sequencing was performed on fecal samples collected from 13 COVID‐19 patients and controls. We analyzed the structure of gut microbiota, identified the characteristic bacteria, and selected biomarkers. Further, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) annotations were employed to correlate the taxon alterations and corresponding functions. The gut microbiota of COVID‐19 patients was characterized by the enrichment of opportunistic pathogens and depletion of commensals. The abundance of Bacteroides spp. displayed an inverse relationship with COVID‐19 severity, whereas Actinomyces oris , Escherichia coli , and Streptococcus parasanguini were positively correlated with disease severity. The genes encoding oxidoreductase were significantly enriched in gut microbiome of COVID‐19 group. KEGG annotation indicated that the expression of ABC transporter was upregulated, while the synthesis pathway of butyrate was aberrantly reduced. Furthermore, increased metabolism of lipopolysaccharide, polyketide sugar, sphingolipids, and neutral amino acids were found. These results suggested the gut microbiome of COVID‐19 patients was in a state of oxidative stress. Healthy gut microbiota may enhance antiviral defenses via butyrate metabolism, whereas the accumulation of opportunistic and inflammatory bacteria may exacerbate COVID‐19 progression.
TCT-577 Impact of Angiographic Patterns of In-Stent Restenosis on 5 Years Clinical Outcomes in Patients Treated with Cobalt-Chromium Everolimus-Eluting Stent
Authors: Takashi Hiromasa, Shoichi Kuramitsu, Seiichi Hiramori, Kyohei Yamaji, Makoto Hyodo, Yoshimitsu Soga, Shinichi Shirai, Kenji Ando
Journal: Journal of the American College of Cardiology (2018)
Miscellany.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cancerology, Immunogenetic, and Pharmacology Week
Journal: JNCI Journal of the National Cancer Institute (1983)

Cancerology, Immunogenetic, and Pharmacology Week JNCI: Journal of the National Cancer Institute, Volume 70, Issue 4, April 1983, Page 787, https://doi.org/10.1093/jnci/70.4.787-a Published: 01 April 1983
Collapsing glomerulopathy following SARS-CoV-2 adenovirus-vector–based vaccine: report of 2 cases
Authors: Precil D. Neves, Renato A. Caires, Manoel P. Guimarães, Elerson C. Costalonga, Livia B. Cavalcante, Verônica T. Costa e Silva, Francisco Z. Mattedi, Leonardo F. Santana, Antônio A. Teixeira-Júnior, Orlando V. Gomes, Gyl E. Silva, Emmanuel A. Burdmann, Luiz F. Onuchic
Journal: Kidney International (2022)